The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EMBER-Lung: Electronic medical record boosting molecular testing in early stage NSCLC.
 
Willdragon Wang
No Relationships to Disclose
 
Dylan Scholes
No Relationships to Disclose
 
Megan Roy
Speakers' Bureau - AstraZeneca
 
Sunil Singhal
No Relationships to Disclose
 
John Kucharczuk
No Relationships to Disclose
 
Doraid Jarrar
No Relationships to Disclose
 
Jarrod Predina
No Relationships to Disclose
 
Taine Pechet
Employment - University of Pennsylvania
Leadership - University of Pennsylvania
 
Lova Sun
Consulting or Advisory Role - Bayer; Genmab/Seagen; Genzyme; MJH Life Sciences; Regeneron
Research Funding - Abbvie (Inst); Blueprint Medicines (Inst); Erasca, Inc (Inst); Frontier Medicines (Inst); Immunocore (Inst); IO Biotech (Inst); Merus (Inst); ORIC Pharmaceuticals (Inst); Seagen (Inst)
 
Aditi Singh
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Precision HEOR (I)
Research Funding - Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Jazz Pharmaceuticals (Inst)
 
Roger Cohen
Consulting or Advisory Role - Actuate Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Cantargia AB (Inst); Chugai Pharma (Inst); F-Star Biotechnology (Inst); Innate Pharma (Inst); Xencor (Inst)
 
Corey Langer
No Relationships to Disclose
 
Charu Aggarwal
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novocure; Pfizer; Sanofi/Regeneron; Takeda
Speakers' Bureau - AstraZeneca (I)
Research Funding - AstraZeneca/MedImmune (Inst); Candel Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Loxo@Lilly (Inst); Merck Sharp & Dohme (Inst)
 
Melina Marmarelis
Stock and Other Ownership Interests - Johnson & Johnson; Merck
Honoraria - AstraZeneca; Blueprint Medicines; Janssen Oncology; Novocure; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Astra Zeneca; Janssen Oncology; NEUVOGEN; Regeneron
Research Funding - AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Regeneron